https://www.selleckchem.com/pr....oducts/ac-devd-cho.h
Further work is needed to identify subgroups of patients who may benefit from available treatment escalation approaches. As treatment paradigms evolve for prostate cancer, recent evidence continues to demonstrate benefit for the use of local therapy, both in patients with organ-confined disease and, more increasingly, in those with limited metastatic or locally recurrent disease. Further work is needed to identify subgroups of patients who may benefit from available treatment escalation approaches. Bladder cancer is the 10th most co
Like
Comment
Share
